At the World Economic Forum in Davos, Argentine President Javier Milei struck a pragmatic chord on trade, declaring China an essential partner without jeopardizing ties to the United States. Speaking to Bloomberg Editor-in-Chief John Micklethwait at Bloomberg House, Milei emphasized open markets as key to Argentina’s revival, a stance that underscores his libertarian push amid global tensions. Meanwhile, Sanofi CEO Paul Hudson, in a CNBC Squawk Box interview, navigated the choppy waters of U.S. drug pricing and President Trump’s policies, positioning artificial intelligence as a game-changer for efficiency.
Milei’s comments reflect Argentina’s economic pivot. ‘China is an important trading partner and sees no conflict in terms of the South American nation’s ties with the US,’ he told Micklethwait, signaling a multipolar trade strategy. This comes as Argentina seeks investment, with Milei eyeing AI hubs and deregulation to lure tech giants, building on meetings with figures like Elon Musk and Peter Thiel.
Hudson’s Davos appearance highlighted pharma’s precarious position. Reacting to Trump’s speech urging Europe to pay more for drugs—up to 200-300% higher—Hudson expressed cautious optimism. ‘I’m encouraged by the energy for removing health inequity,’ he said on CNBC, stressing access to innovation while bracing for pricing pressures.
Milei’s Trade Gambit in a Fractured World
Milei’s Davos rhetoric aligns with his domestic reforms slashing inflation from 300% to around 30%, per recent X posts and reports. At the forum, he defended free markets against state overreach, echoing his 2024 speech but now with tangible progress like fiscal surpluses. His openness to China counters U.S. tariff threats, positioning Argentina as a bridge in U.S.-China trade frictions (The Guardian).
Posts on X amplify Milei’s vision for Argentina as an AI powerhouse, citing cheap energy and business freedom. ‘Argentina will become an AI hub. We have everything, land, cold weather, cheap energy, and human capital,’ Milei stated earlier, per Dr. Eli David. This dovetails with Hudson’s AI enthusiasm, hinting at potential synergies in biotech investment.
Trump’s Davos address added urgency, backing off Greenland tariffs but pressing Europe on drug costs. Milei’s trade flexibility could appeal to pharma firms eyeing South American expansion amid U.S.-Europe pricing disputes (Fortune).
Hudson’s Blueprint for Pharma Resilience
Hudson detailed Sanofi’s strategy amid patent cliffs and $300 billion in looming revenue losses industrywide. ‘Innovation is the only thing that can protect us,’ he told CNBC hosts, citing top-decile growth excluding obesity drugs and a reinvented R&D process. Sanofi aims for double-digit growth over five years, with late-stage pipeline readouts imminent.
On rare diseases, where patient pools are tiny, Hudson underscored duty and profitability. ‘We’re one of the world’s leaders in rare diseases… We’ve been able to run a successful business,’ he noted, pointing to launches like rilzabrutinib for immune thrombocytopenia (ITP). This balances high-volume immunology with niche therapies (CNBC).
Trump’s push for equitable pricing looms large. Hudson referenced talks with Dr. Mehmet Oz and the administration on health inequities, warning that failed European negotiations could trigger U.S. controls. Yet, Sanofi’s commercial strength—strong Q3 results—and resource allocation offer buffers.
AI’s Radical Overhaul of Drug Discovery
Hudson positioned AI as transformative. ‘AI will make us a bit more efficient and the cost and speed will change,’ he said, describing its use in governance: agents provide dispassionate views at meetings, stripping bias. Sanofi, an early adopter, integrates AI across R&D to raise bars for patients.
This builds on prior statements. In a Fortune interview, Hudson called OpenAI’s potential ‘insane’ for pharma, which spends up to $4 billion per drug. McKinsey detailed Sanofi’s end-to-end AI shift, enhancing operations and decisions (McKinsey; Fortune).
Recent PharmExec profiled Hudson’s ‘mindset for miracles,’ navigating policy, tech, and science. With biology’s pace fixed, AI accelerates decisions, promising more medicines faster—a boon as pricing debates intensify (PharmExec).
Trump Policies Reshape Global Pharma Dynamics
Hudson addressed Trump’s challenge to Europe directly. ‘The challenge the president put down for Europe is also important,’ he said, advocating value demonstration for therapies that save lives and boost productivity. Sanofi’s immunology pipeline, dubbed ‘perhaps the world’s best,’ underpins this.
Broader industry faces headwinds: Novo Nordisk, Pfizer grapple with pricing deals and patent losses (CNBC, Jan. 21, 2026). Hudson’s resilience pitch—innovation plus execution—aims to thrive amid uncertainty, with AI as the efficiency engine.
Milei’s pro-trade stance could open doors. Argentina’s deregulation and AI ambitions align with pharma’s needs for cost-effective development sites, potentially intersecting with Sanofi’s global ambitions as Trump-era policies force recalibrations.
Pipeline Progress and Profit Pressures
Sanofi’s late-stage assets target unmet needs, from immunology to rare diseases. Hudson highlighted pulling the pipeline through, with readouts in 12-24 months validating the strategy. Stock dips reflect sector woes, but Hudson bets on execution.
Discounts—61% on select drugs for Medicare/Medicaid—and Trump Rx participation test margins, yet top-line growth and launches like those in ITP signal momentum. ‘We’re delivering superb performance,’ Hudson affirmed.
As Davos fades, Milei’s trade openness and Hudson’s AI-driven innovation frame pharma’s path forward. In a world of tariffs and pricing wars, those betting on breakthroughs may outpace the field.
WebProNews is an iEntry Publication